What is the leading cause of chronic renal failure (end‑stage kidney disease) worldwide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Leading Cause of Chronic Renal Failure Worldwide

Diabetes is the leading cause of chronic kidney disease and end-stage renal disease (kidney failure) worldwide, accounting for approximately 40-50% of all cases requiring dialysis or transplantation. 1, 2

Primary Etiologies of End-Stage Kidney Disease

Diabetes as the Dominant Cause

  • Diabetic kidney disease (DKD) has become the single most common cause of kidney failure in the United States, Europe, and most developed countries, representing roughly 40% of new ESRD cases in the U.S. and approximately 50% globally. 1, 2

  • In the U.S., 66-86% of patients with end-stage kidney disease have a diagnosis of diabetes, with variation depending on age and race/ethnicity. 1

  • Both type 1 and type 2 diabetes contribute to this burden, though type 2 diabetes accounts for over half of diabetic patients starting dialysis due to its much greater prevalence in the population. 1

Hypertension as the Second Major Cause

  • Hypertension is the second leading cause of chronic kidney disease in developed countries, with approximately 70% of individuals with elevated serum creatinine having hypertension. 3

  • Hypertension creates a dangerous bidirectional relationship—it both causes kidney damage and results from kidney disease, accelerating the rate of GFR decline to 4-8 mL/min per year when poorly controlled. 3

Other Contributing Causes

  • Glomerulonephritis represents another significant cause, accounting for approximately 21.4% of CKD cases globally, with particular importance in younger populations and certain geographic regions. 3, 4

  • In China specifically, chronic glomerulonephritis and diabetes together account for more than 50% of CKD cases. 3

Clinical Implications and Risk Factors

Population-Specific Risks

  • There is considerable racial and ethnic variability in progression to ESRD, with Native Americans, Hispanics (especially Mexican-Americans), and African-Americans having substantially higher risks than non-Hispanic whites with type 2 diabetes. 1

  • Among diabetic patients, 20-40% develop evidence of nephropathy, though a smaller fraction of type 2 diabetics progress to ESRD compared to type 1 diabetics. 1

Timeline and Natural History

  • In type 1 diabetes, DKD typically develops after 10 years of disease duration, whereas in type 2 diabetes it may already be present at the time of diagnosis. 2, 3

  • Without intervention, 80% of type 1 diabetic patients with sustained microalbuminuria progress to overt nephropathy over 10-15 years, and 50% develop ESRD within several years thereafter. 1

Mortality Impact

  • The presence of diabetic kidney disease increases 10-year all-cause mortality from 11.5% in diabetic patients without kidney disease to 31% in those with kidney disease, with cardiovascular disease causing death more frequently than progression to kidney failure. 1, 2

  • Patients with diabetes on hemodialysis have the worst adjusted survival rates among the ESRD population, with only 55% surviving 3 years and 40% surviving 5 years after dialysis initiation. 1

Common Pitfalls to Avoid

  • Do not assume diabetes is the cause of kidney disease in every diabetic patient—up to 30% of patients with presumed diabetic kidney disease have other causes on kidney biopsy, particularly when atypical features are present (absence of retinopathy, short disease duration, rapid decline, active urinary sediment). 3

  • Do not overlook screening in type 2 diabetes at diagnosis, as 6.5% of newly diagnosed patients already have significant albuminuria and 28% already have hypertension. 3

  • Recognize that the contribution of diabetes to ESRD prevalence has begun to moderate in recent years, possibly reflecting improved management with renin-angiotensin system blockade and newer glucose-lowering agents. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diabetic Kidney Disease Progression and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Chronic Kidney Disease Causes and Risk Factors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Key Evidence‑Based Facts on Early‑Onset Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the appropriate management for a patient with an ear infection and lower back pain, considering their history of diabetes, hypertension, hyperlipidemia, diabetic nephropathy, and a single functioning kidney?
Can hyperglycemia be caused by missed dialysis in a patient with diabetes type 2 (diabetes mellitus type 2) and end-stage renal disease (ESRD) who has missed dialysis for one week and now presents with elevated blood glucose levels and confusion?
What are the primary pharmacological considerations for a patient with diabetic nephropathy?
What are the effects of uncontrolled diabetes on the kidneys in a patient with a history of diabetes?
What is the diagnosis and management for a patient with type 1 diabetes mellitus (DM) and chronic kidney disease (CKD) presenting with fever, flank pain, impaired renal function, and signs of infection?
Is an elevated hemoglobin A1c a risk factor for patients undergoing venous interventions (e.g., venous stenting, angioplasty, thrombectomy, or varicose‑vein procedures)?
How should Lotemax (loteprednol etabonate) 0.5% ophthalmic suspension be dosed and monitored for postoperative ocular inflammation, and what are its contraindications and alternative therapies?
How should I assess and treat a burn injury, including cooling, analgesia, tetanus prophylaxis, wound care, fluid resuscitation, and criteria for referral to a burn center?
What are the target serum methotrexate concentrations for high‑dose methotrexate (≥1 g/m²) at 24, 48, and 72 hours, and how should the treatment be adjusted if the levels exceed these targets?
What should be included in a comprehensive pre‑operative surgical note for a [age]-year‑old [male/female] undergoing [procedure] under [general/regional] anesthesia?
What is the first‑line pharmacologic treatment for a 12‑to‑17‑year‑old adolescent with panic disorder and no contraindicating medical or psychiatric conditions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.